FranceFrance

EFSA to discuss re-authorisation of transgenic Mon810 maize

25.05.2009

Paris/Parma – Agrobiotech-sceptical France wants the European food watchdog EFSA to restart its current review of marketing re-authorisation of transgenic Mon810 maize, which is at present the only GM crop allowed to be planted in the EU on a commercial scale. According to EU insiders, the initiative is backed by 18 member states, who signed a letter sent to the EFSA. As a reaction, the EFSA now invited the EU member states on May 21 to name two experts per member state to discuss the topic with EFSA representatives on May 26.
In mid-April, German Agriculture Minister Ilse Aigner had prohibited planting of Mon810 referring to studies presented by Luxembourg that had forbidden Mon810 cultivation only two weeks before. The studies suggest that there might be a fatal effect of the Bt-toxin Cry1Ab, which is used in Mon810 but also in organic farming, on non-target organisms such as ladybugs. The studies however had been critisised within the scientific community because the toxic effect observed was stronger at low and medium concentrations than at high concentrations, which is not in line with any known toxicity model. GM proponents said, that not one case of negative impact of Mon810 cultivation has been reported since the crop has been planted on a commercial scale in Spain (since 1998). They now fear that France will start a politically-motivated campaign against the Mon810 line, that is backed by a majority of the EU member states.

FranceFrance

19.08.2011

Marcy l’Etoile – French in vitro diagnostics group Biomérieux S.A. informed the markets that it has acquired Argene, a French company specialising in molecular diagnostics for immuno­compromised patients. Biomérieux said it was...

FranceFrance

17.08.2011

Paris – A team consisting of French scientists and biotech start-up Epixis SA has developed a novel hepatitis C vaccine based on retrovirus-derived virus-like particles (VLPs) pseudotyped with the heterologous viral envelope...

FranceFrance

10.08.2011

Neuilly/New York - Les Laboratoires Servier and Intercept Pharmaceuticals join forces for the development of diabetes drugs. France’s largest independent pharmaceutical company and the US biotech entered into a worldwide ex-U.S....

FranceFrance

20.07.2011

Paris/New Haven - Sanofi pays a $9m milestone payment to Rib-X Pharmaceuticals, Inc. The French pharmaceutical company recently signed worldwide research collaboration and option for license for novel classes of antibiotics...

FranceFrance

12.07.2011

French drug maker Sanofi SA announced mixed results of a late-stage trial of multiple sclerosis drug Lemtrada. The two-year study CARE-MS I is the first of two randomised, Phase 3 clinical trials comparing Sanofi's alemtuzumab to...

FranceFrance

05.07.2011

French Biotech BioAlliance Pharma S.A. has announced plans to raise up toEUR 16.6 million through the sale 3.4 million shares at EUR 4.90 in a rightsissue. The price is a 20% discount to BioAlliance's closing price of EUR6.10...

FranceFrance

14.06.2011

Paris – Pulmonary arterial hypertension (PAH), a severe disease of the arterial blood vessels in the lungs, leads to chronically elevated pulmonary artery pressure and remodelling of the small pulmonary arteries (SMPs) as a...

Displaying results 21 to 30 out of 268

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/2/article/efsa-to-discuss-re-authorisation-of-transgenic-mon810-maize.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.23 EUR6.03%
  • VITA 343.96 EUR4.49%
  • WILEX2.36 EUR4.42%

FLOP

  • CYTOS0.26 CHF-3.70%
  • MOLOGEN7.10 EUR-2.74%
  • ADDEX4.00 CHF-1.72%

TOP

  • SANTHERA82.95 CHF19.7%
  • MAGFORCE6.50 EUR10.2%
  • LONZA101.10 CHF7.1%

FLOP

  • MOLOGEN7.10 EUR-24.5%
  • WILEX2.36 EUR-24.4%
  • 4SC1.23 EUR-15.2%

TOP

  • SANTHERA82.95 CHF3850.0%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR198.8%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.65 EUR-67.7%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 21.08.2014


Current issue

All issues

Product of the week

Products